Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,890,360
  • Shares Outstanding, K 114,602
  • Annual Sales, $ 306,490 K
  • Annual Income, $ 94,180 K
  • 60-Month Beta 1.15
  • Price/Sales 6.26
  • Price/Cash Flow 19.80
  • Price/Book 4.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.20
  • Number of Estimates 3
  • High Estimate 0.21
  • Low Estimate 0.19
  • Prior Year 0.17
  • Growth Rate Est. (year over year) +17.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.12 +16.82%
on 06/12/20
18.52 -10.96%
on 06/23/20
+1.12 (+7.25%)
since 06/10/20
3-Month
11.57 +42.57%
on 04/16/20
18.52 -10.96%
on 06/23/20
+4.29 (+35.09%)
since 04/09/20
52-Week
9.70 +70.05%
on 03/23/20
18.52 -10.96%
on 06/23/20
+5.59 (+51.19%)
since 07/10/19

Most Recent Stories

More News
Corcept Begins Enrollment in Phase III Pancreatic Cancer Study

Corcept (CORT) enrolls the first patient in the phase III RELIANT study on relacorilant in combination with Abraxane for treating metastatic pancreatic cancer.

MRK : 76.73 (+0.05%)
BMY : 57.43 (-1.17%)
BLRX : 1.8100 (+1.69%)
CORT : 16.50 (-1.52%)
Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CELGZ : 0.47 (+2.15%)
CORT : 16.50 (-1.52%)
3 Low Risk Stocks That Can Prosper During a Recession

As we plunge further into a recession, safe stocks such as Salesforce (CRM), Vertex Pharmaceuticals Inc (VRTX), and Corcept Therapeutics Incorporated (CORT) can help weather the storm. On June 8th,...

CRM : 198.88 (-0.93%)
VRTX : 294.45 (-0.32%)
CORT : 16.50 (-1.52%)
Clinical Trials for new Therapies Providing Hope for Metastatic Breast Cancer Patients

, /PRNewswire/ -- Metastatic breast cancer (also called stage IV) is breast cancer that has spread to another part of the body, most commonly the liver, brain, bones, or lungs. Metastatic disease is NOT...

ONCY : 1.9100 (+1.60%)
ONC.TO : 2.59 (+2.37%)
PFE : 33.83 (+1.11%)
LLY : 163.36 (-1.86%)
NVTA : 33.47 (-2.42%)
CLVS : 6.62 (-1.19%)
CORT : 16.50 (-1.52%)
Corcept Therapeutics to Present Data at the American Association of Cancer Research Annual Meeting

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

MRK : 76.73 (+0.05%)
CORT : 16.50 (-1.52%)
Why Is Corcept (CORT) Up 8.2% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CORT : 16.50 (-1.52%)
Has Corcept Therapeutics (CORT) Outpaced Other Medical Stocks This Year?

Is (CORT) Outperforming Other Medical Stocks This Year?

CORT : 16.50 (-1.52%)
Corcept Therapeutics to Present Data at the American Society of Clinical Oncology Annual Meeting

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 16.50 (-1.52%)
Corcept (CORT) Q1 Earnings Top Estimates, Revenues Rise Y/Y

Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.

MRK : 76.73 (+0.05%)
BMY : 57.43 (-1.17%)
CORT : 16.50 (-1.52%)
ATXI : 9.76 (+0.10%)
Corcept Therapeutics (CORT) Tops Q1 Earnings and Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of 19.05% and 7.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

CORT : 16.50 (-1.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade CORT with:

Business Summary

Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol....

See More

Key Turning Points

2nd Resistance Point 17.03
1st Resistance Point 16.76
Last Price 16.50
1st Support Level 16.30
2nd Support Level 16.10

See More

52-Week High 18.52
Last Price 16.50
Fibonacci 61.8% 15.15
Fibonacci 50% 14.11
Fibonacci 38.2% 13.07
52-Week Low 9.70

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar